<?xml version='1.0' encoding='utf-8'?>
<document id="29030176"><sentence text="Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex."><entity charOffset="93-106" id="DDI-PubMed.29030176.s1.e0" text="valproic acid" /><entity charOffset="111-121" id="DDI-PubMed.29030176.s1.e1" text="divalproex" /><pair ddi="false" e1="DDI-PubMed.29030176.s1.e0" e2="DDI-PubMed.29030176.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29030176.s1.e0" e2="DDI-PubMed.29030176.s1.e1" /></sentence><sentence text="Valproic acid (VPA) is an older first-line antiepileptic drug with a complex pharmacokinetic (PK) profile, currently under investigation for several novel neurologic and non-neurologic indications"><entity charOffset="0-13" id="DDI-PubMed.29030176.s2.e0" text="Valproic acid" /><entity charOffset="15-18" id="DDI-PubMed.29030176.s2.e1" text="VPA" /><pair ddi="false" e1="DDI-PubMed.29030176.s2.e0" e2="DDI-PubMed.29030176.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29030176.s2.e0" e2="DDI-PubMed.29030176.s2.e1" /></sentence><sentence text=" Our study objective was to design and validate a mechanistic model of VPA disposition in adults and children; and evaluate its predictive performance of drug-drug interactions (DDIs)"><entity charOffset="71-73" id="DDI-PubMed.29030176.s3.e0" text="VPA" /></sentence><sentence text=" This study expands upon existing physiologically based pharmacokinetic (PBPK) models for VPA by incorporating UGT enzyme kinetics and an advanced dissolution, absorption, and metabolism (ADAM) model for extended-release (ER) formulation"><entity charOffset="90-92" id="DDI-PubMed.29030176.s4.e0" text="VPA" /></sentence><sentence text=" PBPK models for VPA IR and ER formulations were constructed using Simcyp Simulator (Version 15)"><entity charOffset="17-19" id="DDI-PubMed.29030176.s5.e0" text="VPA" /></sentence><sentence text=" First-order absorption was used for the immediate-release (IR) formulation and the ADAM model, including a controlled-release profile, for ER" /><sentence text=" Data from twenty-one published clinical studies were used to assess model performance" /><sentence text=" The model accurately predicted the concentration-time profiles of IR formulation for single-dose and steady-state doses ranging from 200mg to 1000mg" /><sentence text=" Similarly profiles were also simulated for ER formulation after a single-dose and steady-state doses of 500mg and 1000mg, respectively" /><sentence text=" In addition, simulated PK profiles agreed well with the observed data from studies in which VPA ER formulation was given to pediatric patients and VPA IR formulation to adult patients with cirrhosis"><entity charOffset="93-95" id="DDI-PubMed.29030176.s10.e0" text="VPA" /><entity charOffset="148-150" id="DDI-PubMed.29030176.s10.e1" text="VPA" /><pair ddi="false" e1="DDI-PubMed.29030176.s10.e0" e2="DDI-PubMed.29030176.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29030176.s10.e0" e2="DDI-PubMed.29030176.s10.e1" /></sentence><sentence text=" The model was further validated with individual adult data from a Phase I clinical trial consisting of eight cohorts after IV infusion of VPA with doses ranging from 15 to 150mg/kg"><entity charOffset="139-141" id="DDI-PubMed.29030176.s11.e0" text="VPA" /></sentence><sentence text=" Co-administrations of VPA as an enzyme-inhibitor with victim drug phenytoin or lorazepam, as well as a substrate with enzyme inducer carbamazepine or phenobarbital, were simulated with the model to evaluate drug-drug interaction"><entity charOffset="23-26" id="DDI-PubMed.29030176.s12.e0" text="VPA" /><entity charOffset="67-76" id="DDI-PubMed.29030176.s12.e1" text="phenytoin" /><entity charOffset="80-89" id="DDI-PubMed.29030176.s12.e2" text="lorazepam" /><entity charOffset="134-147" id="DDI-PubMed.29030176.s12.e3" text="carbamazepine" /><entity charOffset="151-164" id="DDI-PubMed.29030176.s12.e4" text="phenobarbital" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e0" e2="DDI-PubMed.29030176.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e0" e2="DDI-PubMed.29030176.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e0" e2="DDI-PubMed.29030176.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e0" e2="DDI-PubMed.29030176.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e0" e2="DDI-PubMed.29030176.s12.e4" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e1" e2="DDI-PubMed.29030176.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e1" e2="DDI-PubMed.29030176.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e1" e2="DDI-PubMed.29030176.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e1" e2="DDI-PubMed.29030176.s12.e4" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e2" e2="DDI-PubMed.29030176.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e2" e2="DDI-PubMed.29030176.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e2" e2="DDI-PubMed.29030176.s12.e4" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e3" e2="DDI-PubMed.29030176.s12.e3" /><pair ddi="false" e1="DDI-PubMed.29030176.s12.e3" e2="DDI-PubMed.29030176.s12.e4" /></sentence><sentence text=" The simulated serum concentration-time profiles were within the 5th and 95th percentiles, and the majority of the predicted area-under-the-curve (AUC) and peak plasma concentration (Cmax) values were within 25% of the reported average values" /><sentence text=" The comprehensive VPA PBPK model defined by this study may be used to support dosage regimen optimization to improve the safety and efficacy profile of this agent under different scenarios"><entity charOffset="19-31" id="DDI-PubMed.29030176.s14.e0" text="VPA" /></sentence><sentence text="" /></document>